165 related articles for article (PubMed ID: 21625106)
1. The impact of paricalcitol on left ventricular hypertrophy.
Cozzolino M; Ronco C
Contrib Nephrol; 2011; 171():161-165. PubMed ID: 21625106
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
4. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Matias PJ; Jorge C; Ferreira C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Clin J Am Soc Nephrol; 2010 May; 5(5):905-11. PubMed ID: 20203163
[TBL] [Abstract][Full Text] [Related]
5. Restoring the physiology of vitamin D receptor activation and the concept of selectivity.
Cozzolino M; Brenna I; Volpi E; Ciceri P; Mehmeti F; Cusi D
Contrib Nephrol; 2011; 171():151-156. PubMed ID: 21625104
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D receptor activation and prevention of arterial ageing.
Cozzolino M; Stucchi A; Rizzo MA; Soldati L; Cusi D; Ciceri P; Brenna I; Elli F; Gallieni M
Nutr Metab Cardiovasc Dis; 2012 Jul; 22(7):547-52. PubMed ID: 22633189
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
[TBL] [Abstract][Full Text] [Related]
8. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Andress D
Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.
Nuijten M; Andress DL; Marx SE; Curry AS; Sterz R
Clin Drug Investig; 2010; 30(8):545-57. PubMed ID: 20586517
[TBL] [Abstract][Full Text] [Related]
10. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
11. Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol).
Bover J; Dasilva I; Furlano M; Lloret MJ; Diaz-Encarnacion MM; Ballarin J; Cozzolino M
Curr Vasc Pharmacol; 2014 Mar; 12(2):313-23. PubMed ID: 23713879
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
Thadhani R; Appelbaum E; Pritchett Y; Chang Y; Wenger J; Tamez H; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Packham D; Singh B; Zehnder D; Shah A; Pachika A; Manning WJ; Solomon SD
JAMA; 2012 Feb; 307(7):674-84. PubMed ID: 22337679
[TBL] [Abstract][Full Text] [Related]
14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor activation and cardiovascular disease.
Gonzalez-Parra E; Rojas-Rivera J; Tuñón J; Praga M; Ortiz A; Egido J
Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv17-21. PubMed ID: 23258805
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
17. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cai P; Tang X; Qin W; Ji L; Li Z
Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
[TBL] [Abstract][Full Text] [Related]
18. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
Covic A; Voroneanu L; Goldsmith D
Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease.
Sözel H; Köksoy S; Ozdem S; Yılmaz F; Bora F; Ersoy FF
Int Urol Nephrol; 2020 Aug; 52(8):1563-1570. PubMed ID: 32405698
[TBL] [Abstract][Full Text] [Related]
20. Importance of vitamin D receptor activation in clinical practice.
Cozzolino M; Fallabrino G; Pasho S; Olivi L; Ciceri P; Volpi E; Gallieni M; Brancaccio D
Contrib Nephrol; 2009; 163():213-218. PubMed ID: 19494616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]